Hartaj Singh
Stock Analyst at Oppenheimer
(1.82)
# 3,204
Out of 5,182 analysts
106
Total ratings
48.42%
Success rate
-5.79%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $21.18 | +74.69% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $748.87 | +20.18% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $138.99 | -10.07% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $436.27 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $63.63 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $571.73 | +4.94% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $50.96 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.59 | +178.55% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.87 | +3,108.56% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.80 | +400.00% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.06 | +3,673.58% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $13.50 | +62.96% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.83 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $4.76 | +13,555.46% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $19.67 | +52.52% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $21.18
Upside: +74.69%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $748.87
Upside: +20.18%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $138.99
Upside: -10.07%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $436.27
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $63.63
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $571.73
Upside: +4.94%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $50.96
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.59
Upside: +178.55%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.87
Upside: +3,108.56%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.80
Upside: +400.00%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.06
Upside: +3,673.58%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $13.50
Upside: +62.96%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $0.83
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $4.76
Upside: +13,555.46%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $19.67
Upside: +52.52%